SINTAHO

Sintaho focuses on three primary business segments: High-potency/Cytotoxic APIs, Peptides, and XDC Compounds. The product applications have been approved by more than 30 countries such as China, the United States, Canada and the European Union, resulting in product sales thereof. Sintaho is able to provide sophisticated CDMO and CMO services to our global partners by owning the dedicated cytotoxic API production lines, OEB5-level high-potency API production lines, and peptide production lines... Chongqing Sintaho Pharmaceutical Co., Ltd. (hereinafter called "Sintaho"), founded in 2016, is a leading Active Pharmaceutical Ingredient (API) enterprise with distinctive characteristics, perfect GMP supporting systems, and long-time GMP compliance. Sintaho has full chain operation capabilities spanning R&D, production, registration, domestic and international marketing of APIs. Over the years, Sintaho has been honored with numerous titles, including National High-tech Enterprise, National..

Primary location: Chongqing China